--- title: "[HK IPO Subscription] Kefu Medical Subscription Strategy" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/40259751.md" description: "Today, $XIZHI TECH-P(01879.HK) was listed, surging a maximum of 440%+ to HKD 996. It truly lives up to its optoelectronic concept, really fierce. One board lot netted over 12k, even though one lot only has 15 shares... Brother Ergou went all in with margin financing across all three of his accounts, and two of them got allocated. However, he sold everything in the grey market yesterday afternoon, securing profits early. Feels like he missed out on a lot... I. Basic Information $COFOE MEDICAL(01187.HK), established in 2007, has been deeply involved in the home medical device industry for nearly 20 years..." datetime: "2026-04-28T13:50:28.000Z" locales: - [en](https://longbridge.com/en/topics/40259751.md) - [zh-CN](https://longbridge.com/zh-CN/topics/40259751.md) - [zh-HK](https://longbridge.com/zh-HK/topics/40259751.md) author: "[王二狗子](https://longbridge.com/en/profiles/1050883.md)" --- # [HK IPO Subscription] Kefu Medical Subscription Strategy Today, $XIZHI TECH-P(01879.HK) listed, surging up to 440%+ to HKD 996. It's truly fierce, living up to its photonics concept. One lot netted over HKD 12,000 in profit, even though one lot is only 15 shares... Brother Er Gou went all in with margin across all three of his accounts, and two of them hit. However, he sold everything in the grey market yesterday afternoon, taking profits early. Feels like he missed out on a lot of gains... ## **I. Basic Information** $COFOE MEDICAL(01187.HK), established in 2007, has been deeply involved in the home medical device industry for nearly 20 years. It is committed to providing users with lifelong trusted medical and health products and one-stop solutions. It has over 200 product categories and tens of thousands of product specifications, covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine physiotherapy. It has now developed into a leading enterprise in full-lifecycle personal health management integrating R&D, production, sales, and service. In terms of domestic revenue in 2024, it ranks second among all home medical device enterprises in China. Specifically, in terms of domestic revenue in 2024, the company's home rehabilitation aid products rank first, with a market share of 2.4%. In 2024, China's home rehabilitation aid product market accounted for 23.5% of China's home medical device market.... ## **II. IPO Information** Company Name & Code: Kefu Medical (06613.HK) Issue Price: 39.33KD Minimum Subscription Fee: HKD 3,972.67 (1 lot = 100 shares) Subscription Period: April 27 to April 30, closing this Thursday Allotment Results Announcement: May 4 Listing Date: May 6 Shares on Offer: 27 million shares, representing 11.45% of total share capital **Allocation Mechanism: Mechanism B** Market Cap: HKD 9.278 billion **Green Shoe: Yes...** Cornerstone Investors: 12 cornerstone investors subscribed for 35.7% in total, the lineup is quite ordinary **Sponsors: Huatai, BNP!** ## **III. Fundamental Situation** In 2023, 2024, and 2025, the company achieved revenues of approximately RMB 2.854 billion, RMB 2.983 billion, and RMB 3.387 billion respectively, with a compound annual growth rate (CAGR) of 8.9%. During this period, the company's net profits were RMB 254 million, RMB 312 million, and RMB 372 million respectively, with a CAGR of 21%... The company belongs to the traditional medical device industry, with revenue growth slowing down noticeably. However, its profitability is relatively solid, and profit levels are continuously improving.... ## **IV. Subscription Strategy** 1\. The company's fundamentals are average, nothing much to elaborate on... For A-H shares, the main focus is on the discount. Currently, the A-share price is RMB 52.35, and the HK share pricing is HKD 39.33, representing a 36% discount for HK shares compared to A shares. The sincerity seems slightly insufficient.... 2\. The concept is very ordinary, very traditional... 3\. The company is issuing under Mechanism B, with a total of 27,000 lots for Group A and B combined. The supply isn't small, and the popularity isn't high, so the winning rate might be relatively higher. 4\. No green shoe, but there are cornerstone investors subscribing for 36%. The lineup is very ordinary, feels like they're just making up the numbers... 5\. Currently, Tianxing Medical is also in its IPO period, causing a conflict. The risk-reward ratio is very low, and there's little point in participating. Brother Er Gou doesn't plan to go for it... **Subscription Score: 5 points** **(**9-10 points: go all in with margin; 7-8 points: can use some margin; 6 points: sneak in a small speculative play; 5 points: forget it, not worth it) _**Of course, this is only Brother Er Gou's personal trading strategy and does not constitute any investment advice....**_ _**Follow Brother Er Gou for a smooth journey in HK IPO investing ~~~**_ $STAR SPORTS MED(01609.HK) _**Disclaimer:**_ _1\. This article represents only one person's opinion and should not be taken as any investment advice or recommendation. The securities market is ever-changing and unpredictable, with constant ups and downs. Caution is still required in handling this._ _2\. When making any investment decisions or conducting any investment transactions, you must act within your means, handle it calmly based on your own financial situation, or consult relevant professional investment institutions._ _3\. If you find this article somewhat interesting, likes, comments, and shares are welcome. The author will be most grateful._ ### Related Stocks - [301087.CN](https://longbridge.com/en/quote/301087.CN.md) - [01879.HK](https://longbridge.com/en/quote/01879.HK.md) - [01609.HK](https://longbridge.com/en/quote/01609.HK.md) - [01187.HK](https://longbridge.com/en/quote/01187.HK.md) ## Comments (1) - **不红不卖 · 2026-04-28T17:14:31.000Z**: Non-tech AH shares are not worth looking at at all.